Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18611187 | 0.86 | ICMT (0.40) | ICMTPPARGLMNAL3MBTL1 | |
| SCHEMBL18591263 | 0.83 | ICMT (0.41) | ICMTCNR2SCN9ACNR1 | |
| SCHEMBL29841210 | 0.83 | ICMT (0.41) | ICMTCNR2SCN9ACNR1 | |
| SCHEMBL20329592 | 0.82 | ICMT (0.51) | ICMTMEN1KMT2APLA2G4ALMNA | |
| SCHEMBL18555286 | 0.82 | ICMT (0.43) | ICMTKMT2ACNR2CNR1ALOX15 | |
| SCHEMBL29546024 | 0.82 | ICMT (0.43) | ICMTKMT2ACNR2CNR1ALOX15 | |
| SCHEMBL18611174 | 0.80 | LMNA (0.55) | ICMTMEN1KMT2APLA2G4ACNR2 | |
| SCHEMBL18555837 | 0.79 | ICMT (0.42) | ICMTCNR2SCN9ACNR1 | |
| Trifluoroacetic Acid SCHEMBL29841176 | 0.79 | KDM4E (0.43) | ICMTMEN1KMT2ALMNA | |
| SCHEMBL20992282 | 0.78 | ICMT (0.47) | ICMTCNR2SCN9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | ICMT 4435/4885PPARG 4564/4885MEN1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.